Bath & Body Works (NYSE:BBWI) Stock Rating Lowered by Barclays

Bath & Body Works (NYSE:BBWI) was downgraded by research analysts at Barclays from an “equal weight” rating to an “underweight” rating in a research report issued on Friday, MarketBeat.com reports. They currently have a $28.00 price target on the stock, down from their prior price target of $31.00. Barclays‘s price target indicates a potential downside of 6.67% from the company’s previous close.

BBWI has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their price target on shares of Bath & Body Works from $42.00 to $39.00 and set a “neutral” rating on the stock in a research report on Thursday, August 29th. Citigroup decreased their price target on shares of Bath & Body Works from $48.00 to $35.00 and set a “neutral” rating for the company in a research report on Tuesday, August 20th. UBS Group cut their price objective on Bath & Body Works from $52.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, August 29th. Morgan Stanley decreased their target price on Bath & Body Works from $56.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, September 5th. Finally, Telsey Advisory Group reiterated an “outperform” rating and issued a $42.00 target price on shares of Bath & Body Works in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.44.

Bath & Body Works Stock Down 5.5 %

Shares of NYSE BBWI opened at $30.00 on Friday. The stock has a market capitalization of $6.57 billion, a PE ratio of 7.26, a P/E/G ratio of 1.01 and a beta of 1.79. The firm has a fifty day moving average of $30.01 and a 200-day moving average of $36.93. Bath & Body Works has a 52-week low of $26.20 and a 52-week high of $52.99.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings results on Wednesday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.02. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.54 billion. Bath & Body Works had a negative return on equity of 41.94% and a net margin of 12.69%. Equities research analysts expect that Bath & Body Works will post 3.18 EPS for the current fiscal year.

Insider Transactions at Bath & Body Works

In related news, CEO Gina Boswell purchased 6,000 shares of Bath & Body Works stock in a transaction dated Wednesday, October 9th. The shares were acquired at an average price of $29.64 per share, with a total value of $177,840.00. Following the completion of the transaction, the chief executive officer now owns 242,987 shares of the company’s stock, valued at approximately $7,202,134.68. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Trading of Bath & Body Works

Institutional investors and hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in shares of Bath & Body Works in the 3rd quarter worth approximately $735,000. Anthracite Investment Company Inc. bought a new position in Bath & Body Works during the third quarter worth $2,921,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Bath & Body Works in the third quarter worth $7,371,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Bath & Body Works during the third quarter valued at $309,000. Finally, Banque Cantonale Vaudoise increased its stake in Bath & Body Works by 46.8% during the third quarter. Banque Cantonale Vaudoise now owns 9,108 shares of the company’s stock valued at $291,000 after purchasing an additional 2,902 shares during the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.

Bath & Body Works Company Profile

Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.